Patent US5599844A successfully refreshed from Google Patents.
US5599844A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1995-09-15
•
Granted: 1997-02-04
•
Expires: 2015-09-15
Abstract
Abstract TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
Inventors
- 👤 David J. Grainger
- 👤 James C. Metcalfe
- 👤 Peter L. Weissberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:31
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/395; A61K31/40; A61P; A61P43/00; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10; A61P9/12; A61P9/14; C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; C07K16/00; C07K16/18; C07K16/22; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/74; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/321; G01N2800/323
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
46 words
A therapeutic method to treat procedural vascular trauma, comprising orally administering to a mammal subjected to the vascular trauma an amount of an agent effective upon oral administration to elevate the level of TGF-beta so as to inhibit the pathological proliferation of vascular smooth muscle cells.
Claim 2
Dependent Claim
46 words
A therapeutic method to treat procedural vascular trauma, comprising orally administering to a mammal subjected to the vascular trauma an amount of an agent effective upon oral administration to elevate the level of TGF-beta so as to inhibit the pathological proliferation of vascular smooth muscle cells.
Claim 3
Dependent Claim
19 words
The therapeutic method of claim 1 wherein stenosis or restenosis of a mammalian blood vessel is reduced or inhibited.
Claim 4
Dependent Claim
19 words
The therapeutic method of claim 1 wherein the procedural vascular trauma is due to a graft or transplant procedure.
Claim 5
Dependent Claim
13 words
The therapeutic method of claim 1 wherein the procedural vascular trauma is angioplasty.
Claim 6
Dependent Claim
19 words
The therapeutic method of claim 1 wherein the agent increases the cell cycle time of the smooth muscle cells.
Claim 7
Dependent Claim
20 words
The therapeutic method of claim 1 wherein the agent elevates the level of TGF-beta by increasing production of TGF-beta mRNA.
Claim 8
Dependent Claim
23 words
The therapeutic method of claim 1 comprising administering a series of doses of the agent effective to maintain an elevated level of TGF-beta.
Claim 9
Dependent Claim
14 words
The method of claim 7 wherein the TGF-beta which is elevated is active TGF-beta.
Claim 10
Dependent Claim
15 words
The therapeutic method of claim 1 wherein the agent comprises trans-2-[4-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or an analog thereof.
Claim 11
Dependent Claim
17 words
The therapeutic method of claim 1 wherein the agent does not include heparin or a heparin peptide.
Claim 12
Independent Claim
34 words
A method for reducing or inhibiting restenosis associated with an angioplasty procedure, which method comprises orally administering to a mammal an amount of an agent effective upon oral administration to elevate levels of TGF-beta.
Claim 13
Independent Claim
34 words
A method for reducing or inhibiting restenosis associated with an angioplasty procedure, which method comprises orally administering to a mammal an amount of an agent effective upon oral administration to elevate levels of TGF-beta.
Claim 14
Dependent Claim
17 words
The method of claim 11 wherein the agent is effective to elevate the level of active TGF-beta.
Claim 15
Dependent Claim
14 words
The method of claim 11 wherein the agent comprises trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or an analog thereof.
Claim 16
Dependent Claim
16 words
The method of claim 11 wherein the agent does not include heparin or a heparin peptide.
Claim 17
Dependent Claim
28 words
The method of claim 11 wherein the agent is orally administered in a series of doses effective to inhibit vascular smooth muscle cell proliferation associated with the procedure.
Claim 18
Dependent Claim
19 words
The method of claim 1 or 11 wherein the agent increases the cleavage of the latent form of TGF-beta.
Claim 19
Dependent Claim
15 words
The method of claim 1 or 11 wherein the agent increases the bioavailability of TGF-beta.
Claim 20
Dependent Claim
19 words
The therapeutic method of claim 1 or 11 wherein the agent is administered before, during, or after said procedure.
References Cited (Backward Citations)
US4235988A
Cited
US5098903A
Cited
US5324736A
Cited
US4442119A
Cited
US5047431A
Cited
US5015666A
Cited
US4879315A
Cited
US5491173A
Cited
WO1985000107A1
Cited
US5284763A
Cited
US4824436A
Cited
US4826672A
Cited
US4859585A
Cited
US4839155A
Cited
EP0260066B1
Cited
US5120535A
Cited
US4973755A
Cited
US5216024A
Cited
US5221620A
Cited
US4997652A
Cited
US5468746A
Cited
US5208019A
Cited
US5268358A
Cited
US5032679A
Cited
US5380716A
Cited
US5304541A
Cited
US5356713A
Cited
US5391577A
Cited
US5242397A
Cited
US5112305A
Cited
US4990538A
Cited
US5049132A
Cited
WO1991015222A2
Cited
WO1991015219A1
Cited
US5140012A
Cited
US5166143A
Cited
US5189046A
Cited
US5192525A
Cited
US5219548A
Cited
US5362424A
Cited
WO1992008480A1
Cited
US5308622A
Cited
US5171217A
Cited
US5280016A
Cited
WO1992018546A1
Cited
US5304325A
Cited
US5238950A
Cited
US5326757A
Cited
US5280109A
Cited
US5288711A
Cited
US5283257A
Cited
US5393763A
Cited
US5385935A
Cited
GB2273873A
Cited
US5453436A
Cited
US5308862A
Cited
US5482949A
Cited
US5472985A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-04 | 2000-08-05 | 2001-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-04 | 2004-08-05 | 2005-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-04 | 2008-08-05 | 2009-02-04 | $7700.00 | Window Closed / Lapsed |